medmix AG

As of June 30, 2026, medmix AG carries a market capitalization of 321.32M, placing it among publicly traded companies globally. Its enterprise value stands at 537.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

medmix AG's next confirmed earnings release is scheduled for February 23, 2027.

As of June 30, 2026, medmix AG has 40.67M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, medmix AG maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, medmix AG's stock has gained approximately 8.27% over the past 52 weeks. The 50-day moving average sits at 9.38, while the 200-day moving average is 9.34.

As of June 30, 2026, medmix AG holds 111.30M in cash and equivalents against 319.40M in total debt, resulting in a net debt position of 147.60M. Total book value stands at 425.00M, with working capital of 99.00M providing operational flexibility.